Project Grant R03TR006462
- Federal Project Grant Award Summary The University of Florida's Division of Sponsored Research received a $152,500 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) effective July 1, 2025, through June 30, 2026. The award funds research to elucidate the molecular mechanisms by which the ubiquitin ligase ITCH restrains aberrant mechanistic target of rapamycin complex 1 (mTORC1) activity in B cells. This investigation addresses immune dysregulation...
- Federal Project Grant Award Summary The University of Florida's Division of Sponsored Research received a $419,375 Project Grant from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350, awarded July 7, 2025, with a completion date of June 30, 2027. This award funds preclinical research and optimization of QTE (Quinone-based Therapeutic Element) therapy for Friedreich's Ataxia (FRDA), a rare inherited neurological disorder characterized by progressive...
- Federal Project Grant Award Summary The University of Alabama at Birmingham received a $149,000 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded February 1, 2026, with completion scheduled for January 31, 2027. The grant supports research to define molecular mechanisms and identify therapeutic strategies for X-linked myopathy with excessive autophagy (XMEA), a rare autophagic vacuolar myopathy caused by pathogenic mutations in the VMA21...
- Federal Project Grant Award Summary The National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded The Trustees of Princeton University a $164,000 Project Grant effective July 1, 2026, through June 30, 2027, to investigate understudied rare disease genes involved in heterotaxy development using zebrafish models. The research will deliver three primary products: (1) functional characterization of candidate proteins implicated in left-right patterning through antisense and...
- Federal Project Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $489,500 project grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on September 3, 2025, with a completion date of September 2, 2027. This award supports the development of patient-centric clinical outcome measures for Multiple Sulfatase Deficiency (MSD), an ultra-rare, fatal neurodegenerative disorder. The project addresses a critical gap in...
- Federal Project Grant Award Summary The University of Florida Division of Sponsored Research received a $420,990 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective May 1, 2026 through April 30, 2027. The award supports the development of an advanced brain-penetrant enzyme therapy for treating Lafora Disease, a fatal autosomal...
- Federal Grant Award Summary The University of Florida received a $294,186 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, effective August 20, 2025, through June 30, 2030. This award supports the CTSA (Clinical and Translational Science Award) Predoctoral T32 training program, which develops and implements a specialized clinical and translational science team training curriculum for paired PhD and combined-degree (MD-PhD) predoctoral...
- Federal Grant Award Summary The University of Utah's Office of Sponsored Projects received a $423,500 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective June 17, 2026, with an ultimate completion date of May 31, 2028. The award funds research to elucidate the pathogenic mechanisms of expanded ZFHX3 (zinc finger homeobox family member 3)...
- Federal Project Grant Award Summary The University of Minnesota's Office of Sponsored Projects Administration received a $440,019 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded June 1, 2026, with a completion date of May 31, 2028. This award funds preclinical research to evaluate nervonic acid as a preventive therapy for cerebral adrenoleukodystrophy (ALD), a rare X-linked neurometabolic disorder characterized by defective peroxisomal...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $156,760 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 1, 2026, with completion targeted for April 30, 2027. The grant funds investigator-initiated basic research aimed at characterizing the catalytic potential and biochemical function of...
Project Grant Award Summary The University of Florida Division of Sponsored Research received a $153,500 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded August 1, 2026, with completion targeted for July 31, 2027. This pilot project conducts foundational research on SCYL2, an understudied protein associated with Arthrogryposis Multiplex Congenita Type 4 (AMC4), a rare developmental disorder characterized by multiple joint contractures, brain malformations, and neurogenic phenotypes including epilepsy. The research investigates whether SCYL2 participates in clathrin-mediated endocytosis (CME) and tests the hypothesis that loss-of-function variants in SCYL2 disrupt endocytic pathways and neuronal differentiation, thereby contributing to AMC4 pathology. The project serves as a foundation for establishing a systematic framework to investigate disease-associated endocytic proteins during development. By studying SCYL2's role in vesicle trafficking and neuronal development, the research aims to elucidate cellular and molecular mechanisms underlying this rare disease while advancing broader understanding of endocytic pathway dysfunction relevant to both rare and common diseases. The work aligns with NCATS' translational science mission to accelerate the development of diagnostics and therapeutics by investigating understudied proteins implicated in rare genetic conditions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $153.5k | 7/7/26 |